MQS Management LLC Acquires New Holdings in Gilead Sciences, Inc. $GILD

MQS Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,297 shares of the biopharmaceutical company’s stock, valued at approximately $366,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GoalVest Advisory LLC raised its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the third quarter worth about $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the second quarter worth about $27,000. Putney Financial Group LLC lifted its holdings in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $30,000. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider directly owned 103,221 shares in the company, valued at $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Truist Financial raised their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Wednesday. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday. Scotiabank boosted their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a report on Wednesday. Finally, The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Twenty-four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $146.44.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom line: Gilead reported Q4 EPS of $1.86 vs. consensus ~$1.83 and revenue roughly $7.9B, powered by HIV and liver‑disease franchises — the core beat is the primary near‑term driver of the rally. Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades/price‑target raises: Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others bumped targets (some to $160–$177+), reinforcing buy/overweight sentiment and supporting the stock pop. Morgan Stanley raises price target
• Positive Sentiment: Yescarta label expansion and pipeline momentum: Positive commentary about CAR‑T (Yescarta) label expansion and new HIV options (Yeztugo) adds optionality to growth expectations. Yescarta label expansion and dividend growth
• Positive Sentiment: Dividend increase: Board raised the quarterly payout to $0.82 (3.8% increase), supporting income investors and reducing equity downside for dividend‑focused holders. Dividend announcement
• Neutral Sentiment: Investor commentary and transcripts: Earnings call and slides are available for detail on unit trends and margin commentary — useful for modeling but not an immediate directional driver. Earnings call transcript
• Neutral Sentiment: Short‑interest items in recent filings show no meaningful or reliable signal (reported zero/odd values), so ignore those as noise.
• Negative Sentiment: FY‑2026 guidance came in slightly light: Gilead set EPS guidance of $8.45–$8.85 and revenue guidance ~$29.6–$30.0B, marginally below consensus (~$30.1B / ~$8.69 EPS), which caused an initial after‑hours pullback and remains the main near‑term risk to sustaining the rally. Guidance story
• Negative Sentiment: Some cautious analyst views remain: A few firms (e.g., RBC with a lower PT) kept conservative ratings/targets, which could cap upside if other brokers re‑rate lower or fundamentals disappoint. Analyst notes (RBC)

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $155.80 on Thursday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock has a 50 day moving average price of $129.01 and a 200 day moving average price of $121.77. The stock has a market capitalization of $193.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 51.04% and a net margin of 28.90%.The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.